Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy's Laboratories announced that the U.S. FDA has approved its rituximab biosimilar. This approval strengthens the company's global biosimilars portfolio and opens up the U.S. market for the product, which will be commercialized by Fresenius Kabi.
Aug 01 2026 09:43:09
Dr Reddys Laboratories Ltd - 500124 - Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015
Dr Reddys Laboratories completed a USFDA Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh. The company received a Form 483 with three observations, which will be addressed within the stipulated timeline.
Jul 29 2026 21:38:59
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Dr. Reddy's Laboratories held its Q1 FY27 earnings call, discussing a 5.6% YoY revenue decline and an EBITDA margin of 12.5%. Management expects semaglutide supplies to resume by November, contributing to a strong second half of the fiscal year.
Jul 28 2026 23:08:46
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Change in Management
Dr. Reddy's Laboratories appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. She also joins the Management Council, bringing over two decades of biopharmaceutical leadership experience.
Jul 22 2026 16:29:38
Dr Reddys Laboratories Ltd - 500124 - Board Meeting Outcome for Outcome Of Board Meeting
Dr. Reddy's Laboratories reported Q1 FY27 cons. revenue of ₹8,070.5 cr (down 5.6% YoY) and net profit of ₹443.5 cr (down 69% YoY). The results were impacted by a ₹239.7 cr provision for semaglutide API issues.
Jul 22 2026 16:16:50
Dr Reddys Laboratories Ltd - 500124 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Conference Call Transcript
Dr. Reddy's Laboratories announced a temporary delay in the commercial supply of its Semaglutide injection. An impurity in the API was found during scale-up validation, impacting the supply of 6-7 million pens for Q3-Q4 FY27, which will resume by late October/early November.
Jul 15 2026 16:21:56
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy's Laboratories will announce its Q1 FY27 financial results on July 22, 2026. An earnings call is scheduled for the same day at 7:30 PM IST to discuss the company's performance.
Jul 13 2026 14:35:02
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr. Reddy's Laboratories is experiencing a temporary delay in commercial supplies of its semaglutide product. This is due to certain batches being out of specification because of an issue with the active pharmaceutical ingredient (API). The company is investigating the root cause and implementing measures to ensure product quality.
Jul 09 2026 09:16:23
Read More